$ALKS

Parisi Samuel Joseph sold $687K of ALKS

Parisi Samuel Joseph (VP, Finance (Interim PAO)) sold 16,217 shares of Alkermes plc. (ALKS) at $42.36 ($0.69M total) on 2026-05-29.

Original reporting
SEC EDGAR · Parisi Samuel Joseph
Published May 29, 2026, 10:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALKS
Bearish
medium confidence
Mentioned
$ALKS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALKSBearishLow
01

Why it matters

The disclosure updates insider activity records; it may slightly influence short-term sentiment but does not introduce new company fundamentals.

02

Market read

Traders may monitor for follow-on insider activity, but this single sale is unlikely to drive a durable repricing without accompanying fundamental news.

03

What to watch

No 10b5-1 plan is cited, but the filing still lacks context (e.g., diversification, tax obligations, pre-scheduled personal events), limiting inference about future fundamentals.

Relevance 6/10Novelty 6/10Timing: Filed same day (2026-05-29) as the sale date, for immediate awareness.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Alkermes (ALKS).

Company-level read

Ticker impact

$ALKSBearishMedium confidence
Context

Alkermes (ALKS) is the issuer of an SEC Form 4 showing VP Finance Parisi Samuel Joseph sold 16,217 shares on 2026-05-29.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional insider selling or company-specific news.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan stated; however, insider sales are common and the article provides no new operating/clinical/financial information.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical read-across provided.

None indicated; US-listed issuer only.

None indicated; no cross-border deal/regulatory action mentioned.

Counterpoint

The sale could be liquidity/tax-driven and not a bearish view, especially since insider transactions often occur for non-informational reasons.

Key entities

  • Alkermes plc

    Subject company for the SEC Form 4 insider sale disclosed on 2026-05-29.

  • Parisi Samuel Joseph

    VP, Finance (Interim PAO) who sold 16,217 ALKS shares for ~$687k.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALKSLowAI 8/10

Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?

Alkermes (ALKS) reported early trial results for ALKS 7290, an ADHD drug, showing symptom improvements in adults. The Phase 1b trial had 50 participants and focused on safety and tolerability. ALKS plans further testing, with a Phase 2 trial enrolling 312 participants. Q2 revenue was $496.0M, with R&D expenses at $112.9M. The trial did not establish placebo-adjusted benefits or long-term safety.

$ALKSMed

Goldman Sachs resumes Alkermes stock coverage with neutral rating

Goldman Sachs resumed coverage of Alkermes (NASDAQ:ALKS) with a Neutral rating and $50.00 price target, implying 19% upside. The biopharmaceutical company trades at a high P/E ratio of 108.5. Recent Phase 1b trial results for ALKS 7290 showed positive ADHD treatment outcomes, leading to Buy ratings and higher price targets from other analysts. Alkermes also amended its credit agreement, reducing interest rate spreads.

$ALKSMedAI 8/10

Novel First-in-Class Drug Promising in Early ADHD Study

Alkermes' ALKS 7290, a novel orexin-2 receptor agonist, showed promising results in a phase 1B study for treating adult ADHD, with clinically meaningful symptom improvements and good tolerability. The company plans to enroll participants in a phase 2 study, with data expected in 2027. Experts highlight the potential for a non-stimulant treatment option.

$ALKSMedAI 8/10

Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment - Alkermes (NASDAQ:ALKS)

Alkermes (ALKS) reported positive Phase 1 trial results for ALKS 7290, an experimental ADHD treatment. The study showed dose-dependent symptom reductions and a favorable safety profile. ALKS 7290 targets the orexin 2 receptor, offering a novel approach to ADHD. The company is enrolling patients for a Phase 2 study. ALKS shares rose 1.27% to $43.95 on Monday.